Biomedicine Daily · Thursday, 22 October 2026
CBA FRONTIER INSIGHTS
Roivant, continuing ascent, claims another victory for rare disease drug
Priovant Therapeutics announced positive results for brepocitinib in two Phase 3 studies of non-infectious uveitis. In Clarity-1 and Clarity-2, median time to treatment failure exceeded 48 weeks versus 12 weeks on placebo; treated patients also went 40 weeks without immunosuppressive steroids and met all secondary endpoints, including resolution of macular edema.
Clinical readouts and safety
Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients
Novo Nordisk presented a post hoc analysis of the Phase 3 REDEFINE 1 trial at The Menopause Society 2026 annual meeting. Among 2,309 women, CagriSema produced mean weight loss of 25% at 68 weeks; stratified by menopausal stage, weight loss was 26.7% in premenopausal, 24.8% in perimenopausal, and 23.1% in postmenopausal women, versus 1.7% to 2.6% on placebo.
[Articles] Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
The Dutch single-arm, multicentre, phase 2 NICHE-2 trial showed that patients with locally advanced dMMR colon cancer who received ipilimumab and nivolumab before surgery had 3-year disease-free survival and 5-year overall survival of 100%. The authors consider that this neoadjuvant combination may become a standard treatment option for locally advanced dMMR colon cancer.
Lilly's EloraTZP Combination Cut Weight 23.3% at 48 Weeks in Phase II, Phase III AMPLIFY-1/2 Launched
Lilly reported Phase II data for its combination obesity drug EloraTZP at the EASD congress, showing 23.3% weight loss at 48 weeks. The same day, the company launched AMPLIFY-1 (n=2115, adults with obesity but no diabetes) and AMPLIFY-2 (n=1000).
Medical XpressNew PET imaging approach detects almost all lesions in common form of kidney cancer
At the 2026 EANM annual congress, Arslan and colleagues reported a prospective multicenter study enrolling 68 patients with RCC.
Reforgene Medicine RM001 Pivotal Phase II Beta-Thalassemia Study Achieves Full Transfusion Independence
Reforgene Medicine announced that RM001, its self-developed gene-editing therapy for transfusion-dependent beta-thalassemia, achieved transfusion independence in all enrolled subjects in a pivotal Phase II study, with follow-up exceeding a year. Across all treated subjects to date, hematopoietic reconstitution and freedom from transfusion dependence were achieved, with the longest follow-up reaching five years.
Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea
NEJM has published the full papers of TRIUMPH-1-OSA and TRIUMPH-2-OSA, late-stage trials of once-weekly retatrutide for obstructive sleep apnea, authored by the trial investigator teams. Detailed endpoint and safety data will be added once the full text becomes available.
Medical XpressTestosterone therapy may increase risk of cardiovascular disease in postmenopausal women
A Drexel University team used data from the TriNetX US Collaborative Network to conduct a retrospective cohort study of more than 6,300 propensity score-matched postmenopausal women. Testosterone therapy was associated with a significantly higher risk of composite cardiovascular disease (hazard ratio 8.08, 95% CI 4.72–13.82), with absolute event rates of 3.8% versus 0.5%.
Google NewsVeradermics' hot streak continues with another phase 3 win in hair loss - Fierce Pharma
Regulatory and policy
Nurotron Auditory Brainstem Implant Wins NMPA Approval as China's First Brainstem Stimulation and Signal Extraction Product
Nurotron's auditory brainstem implant (ABI) was approved by the National Medical Products Administration on October 20, 2026. The original article states it is China's first product to perform electrical stimulation and neural signal extraction in the brainstem region, and that it fills a gap in China's auditory brain-computer interface field.
China Approves First tNGS-Based Kit for Detecting Mycobacterium tuberculosis Complex and Resistance Mutations
China has approved the first domestically developed kit based on targeted next-generation sequencing (tNGS) for detecting Mycobacterium tuberculosis complex and drug-resistance gene mutations. The kit provides a testing basis for TB identification, early diagnosis of drug resistance, individualized treatment planning and TB control, moving tNGS TB resistance testing from consensus recommendation to nationally approved clinical testing.
Rasonque (daraxonrasib) wins FDA approval in 40 days under Commissioner's National Priority Voucher
Rasonque (daraxonrasib) received FDA approval for second-line metastatic pancreatic cancer just 40 days after formal acceptance, 203 days ahead of its PDUFA goal date. The review used the Commissioner's National Priority Voucher (CNPV), an accelerated pilot mechanism FDA launched in June 2025 that breaks the traditional review framework used for decades.
Hormone Replacement Therapies Can Help Women with Bothersome Menopausal Symptoms
The FDA has requested that all menopausal hormone therapy (MHT/HRT) products containing estrogen or progestogen remove risk statements on cardiovascular disease, breast cancer, and probable dementia from their boxed warnings, while updating safety information in the labels; these risks remain in the precautions section. Several companies have completed label changes approved by the FDA. The endometrial cancer risk for systemic estrogen-alone products was not required to be removed.
Industry and deals
Hutchmed Outlicenses KRAS-Targeted ATTC Candidate HMPL-A830 to GSK for $110 Million Upfront, Up to $1.295 Billion Total
Hutchmed has granted GSK exclusive rights to develop and commercialize the candidate HMPL-A830 worldwide outside Greater China. Hutchmed will receive an upfront payment of $110 million and is eligible for up to $1.185 billion in development, regulatory and commercial milestone payments plus tiered sales royalties, for a potential total deal value of up to $1.295 billion.
China-Developed Drug Out-Licensing Deal Reaches Over 15.5 Billion Dollars Nominal Value, Second Largest on Record
A license-out deal for a China-developed innovative drug has a nominal total value exceeding 15.5 billion US dollars, ranking second in the history of such out-licensing deals. The consideration includes a 400 million dollar upfront payment, a 110 million dollar one-year anniversary payment, potential milestones exceeding 15 billion dollars, and tiered royalties.
STAT+: Another diabetes association leader is out while review continues
The American Diabetes Association (ADA) notified staff this week that Rita Kalyani, its chief scientific and medical officer, is no longer in her role, effective immediately. The change comes about six weeks after the ADA announced a review of the incident at its June New Orleans annual meeting, where five members were escorted out by armed security for distributing a Diabetes Care editorial calling attention to cuts in federal research funding. That review is ongoing.
Google NewsLycia aims for $228M IPO to generate data on food allergy rival to Xolair - Fierce Biotech
Lycia plans to raise $228 million in an IPO to generate data on a food allergy candidate and position it as a competitor to Xolair.
Google NewsAmbrose Healthcare inks $181M deal for former Pfizer target AM-Pharma - Fierce Biotech
Ambrose Healthcare has struck a $181M deal for AM-Pharma, a former Pfizer target. The original article discloses no further details on deal structure, development stage, or specific indication.
Research papers
CD51 delineates functionally distinct astrocyte subtypes in neural circuits
A research team developed CD51-FLP mice and matching AAV tools, showing that CD51+ and CD51− astrocytes differ in development, molecular expression and neural circuit function. In the developing cortex, CD51+ cells are enriched for synapse-formation genes; chemogenetic stimulation increases excitatory and inhibitory synapses, and Gpc6 knockout abolishes the increase in excitatory synapse formation.
Cold activates a BH2 metabolic network promoting longevity and proteostasis
In C. elegans, cold drives muscle BH2 synthesis via CAT-4; BH2 is converted to BH4 in distal tissues, where PAH-1 uses it to synthesize tyrosine, extending lifespan and improving cross-tissue proteostasis. BH2 or tyrosine supplementation likewise suppressed aggregation of toxic proteins including polyQ74, TDP-43(A382T) and FUS(P525L) in HEK293 cells and ALS iPS-derived motor neurons.
Structural basis for protocadherin-1 recognition by New World hantaviruses
Researchers resolved the structure of the intact ANDV Gn–Gc spike in complex with human PCDH1 at 2.6 Å resolution. The PCDH1 EC1 domain inserts into a central pocket formed by four Gn molecules and contacts four viral glycoproteins.
WEE1 opposes APC/C CDH1 activity to promote S phase entry
WEE1 inhibits APC/C CDH1 activity by directly phosphorylating CDH1 at Tyr91 and Tyr130, thereby promoting timely S phase entry after release from quiescence.
Proteomic atlas of T cell exhaustion defines proteostatic collapse
Researchers built a multi-omic atlas of human T cell exhaustion and found that dysfunctional T cells undergo broad remodeling of protein turnover and ubiquitin regulation, changes not captured by transcriptomic analysis. The E3 ubiquitin ligase RNF166 regulates T cell persistence and anti-tumor function, suggesting proteostasis as a targetable axis for improving immunotherapy.
A bioavailable GPX4 inhibitor for ferroptosis induction in vivo and tumor suppression
Researchers developed KY0418, a systemically administrable GPX4 inhibitor that induces ferroptosis in multiple models and suppresses tumors in a context-dependent manner. The study also links systemic ferroptosis induction to tissue metabolic remodeling and suggests that metastatic spread can be inhibited.
Methyltransferase RsmB chaperones E. coli ribosome assembly by orchestrating the recruitment of ribosomal proteins.
E. coli methyltransferase RsmB coordinates 30S subunit assembly through its chaperone activity. Real-time single-molecule assembly experiments show that its product, 16S m5C967, has limited effect on the affinity of the 16S rRNA 3' domain for ribosomal proteins.
GRP75-dependent SIMPA mediates inter-organellar quality control
Under proteotoxic stress, GRP75-dependent protein aggregates signal through mitochondria-ER contact sites to activate a selective quality-control pathway with SIMPA as a key node, clearing damaged proteins and maintaining mitochondrial integrity. DOI: 10.1038/s41586-026-10733-y.
Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element
The item is a research paper published in Cell on May 31, 2018, at volume 173, pages 1398-1412. The title states that the promoter of the lncRNA gene PVT1 functions as a tumor-suppressor DNA boundary element. The feed did not provide the full text. Link: https://www.cell.com/cell/fulltext/S0092-8674(26)01266-3
Cell Study Finds cMAF Loss in Perivascular Macrophages Causes Blood-Brain Barrier Leakage
A 2026 Cell study found that deleting cMAF in perivascular macrorophages (PVMs) causes immediate blood-brain barrier leakage. The pathway is conserved between humans and mice, and the article accordingly treats PVMs as the macrophage-lineage platform for the next round of cell therapy competition in neurological disease.
Persistent neuronal stress signalling underlies Angelman syndrome phenotypes
Genetic and proteomic analyses of human neurons and mouse models published in Nature show that loss of UBE3A leads to overabundance of asparagine synthetase, which is linked with multiple Angelman syndrome phenotypes. The study connects this mechanism to persistent neuronal stress signalling. DOI: 10.1038/s41586-026-11165-4; https://www.nature.com/articles/s41586-026-11165-4.
Phenotype-cloud reorganization shapes cancer progression and therapeutic adaptation
A research team reports in a bioRxiv preprint that the phenotype cloud reorganizes during breast cancer progression, while after chemotherapy a restricted set of survivor states, supported by diverse transcriptional and regulatory routes, becomes enriched. The study integrates spatial transcriptomic, single-cell, spatial proteomic, bulk-transcriptomic and perturbational data, using graph-neural-network progression coordinates and Field--Flow--Front analysis to identify the shift from a fragmented, high-mixing intermediate state to a stabilized interface-remodelling Front; no comparable stabilization was seen in normal breast tissue.
Medical XpressResearch team develops novel nanobody targeting tumor-fueling fluid to treat late-stage cancer of abdominal lining
A team led by the National Cancer Center Singapore (NCCS) performed multi-omics analysis of 397 ascites samples and identified PAI-1 and S100A10 as key tumor-promoting proteins in the peritoneal metastasis microenvironment. Based on this, they developed E8, a nanobody targeting PAI-1.
Medical XpressGene variants that can cause sudden death mapped
A study led by Vanderbilt University Medical Center and published in Circulation used a high-throughput multiplexed assay of variant effect (MAVE) to map the functional effects of variants in the potassium channel gene KCNQ1. The work distinguishes pathogenic from benign variants in long QT syndrome.
Glycoconjugates tune the viscoelastic signature of mammary tumor progression
This preprint shows in the MMTV-PyMT mouse model that glycoconjugate accumulation drives increased viscoelasticity during mammary tumor progression. Spatial microindentation showed weakened coupling between stiffness and viscoelasticity in late carcinoma; selective enzymatic degradation of sulfated glycosaminoglycans, mucins, or O/N-linked glycans each reduced viscoelasticity without changing stiffness. In vitro, raising matrix viscoelasticity drove MCF10A epithelial cells toward a malignant phenotype via FAK mechanosignaling. The paper proposes viscoelasticity as an independent mechanical feature of breast cancer progression and provides a benchmark for replication in engineered models.
Methods and resources
De novo design of enantioselective artificial metalloenzyme photocatalysts
Sandip Mishra and colleagues publish in Nature a study using generative protein design and directed evolution to build highly enantioselective artificial metalloenzymes that selectively bind metal polypyridine photocatalysts. The evolved proteins support diverse light-driven reactions, achieve high catalyst turnover and catalyst recycling, and can work with commercially available racemic metal complexes.
In vivo Gene Writing with engineered retrotransposons
Researchers computationally reconstructed, screened, and engineered non-LTR retrotransposons to obtain Gene Writers that stably integrate transgenes in human cells via all-RNA delivery. After characterization and optimization, the Gene Writers generated functional CAR-T cells in vivo in a humanized mouse model.
Deep dynamical models of single-cell multiomic velocities predict loss-of-function and rescue perturbations in B cells
This paper reports DynaVelo, a generative deep model that uses a neural ODE to jointly model RNA expression and TF motif accessibility, inferring cell dynamics from single-time-point scRNA+scATAC multiome data, predicting loss-of-function perturbations and nominating rescue targets.
Opinion and commentary
Huge mapping study reveals how your brain tracks what your body is feeling
A Stanford University team led by Josef Parvizi electrically stimulated multiple sites in the insular cortex of 87 patients who had brain electrodes implanted for medical reasons, Nature reports. The posterior insula encoded limb pain, tingling and heat; the middle part mediated visceral sensations such as nausea and chest tightness; and the anterior part communicated with cognitive and emotional brain regions and helped interpret bodily sensations. Lucina Uddin, a cognitive neuroscientist at UCLA, called it one of the most comprehensive studies of the human insula to date, overturning the view that the insula passively reads body signals.
epo.orgEurope’s research breakthroughs face a technology transfer bottleneck
The European Patent Office, together with ASTP and Fraunhofer ISI, has published the first pan-European landscape study of technology transfer offices. A survey of 809 TTOs shows that 90.5% are small or mid-sized, while large offices have six times the staff, support 23 times the research expenditure and receive 16 times the invention disclosures.
In brief
- TONSL/TONSOKU binding to histone H3.1 is required for DNA repair.Science Advances
- A 5 + 1 polyene scaffold that selectively recognizes ergosterol’s conjugated diene uncouples antifungal potency from host toxicityScience
- Cytoplasmic localization of 5hmC reveals RNA hydroxymethylation in breast cancerbioRxiv
- Characterizing the onset and progression of cancer cachexia using routine clinical data.Nature Medicine
- Proteome-wide C-degron activity profiling connects conditional regulation of the CTLH E3 ligase complex to ribosome biogenesis.Molecular Cell
Also today
21 events that did not make today's daily, one table per category, one row per event. Open a category to expand.
Regulatorybepirovirsen · New drug could let some rectal cancer patients skip chemotherapy, radiation and surgery · Cosette lands FDA approval for Evoxac liquid in Sjögren’s disease3 ▾▴
Filings, acceptances, designations, approvals and withdrawals at a regulator.
- bepirovirsenUpdateThe FDA has approved bepirovirsen, from GSK and Ionis Pharmaceuticals, under the brand name Hibsago, in combination with NRTIs for adults with chronic hepatitis B who have no liver fibrosis.FDA
- New drug could let some rectal cancer patients skip chemotherapy, radiation and surgeryUpdateThe FDA has granted accelerated approval to dostarlimab-gxly (Jemperli) for previously untreated stage 2 or 3 dMMR rectal cancer, based on a 154-patient trial in which about 75% of patients avoided surgery, radiation and chemotherapy within two years of follow-up. In an earlier MSKCC study of 50 patients, none showed evidence of cancer, and among 27 followed for three years only one relapsed. Patient Jessica Acosta, 29 with a 6 cm tumor, achieved no evidence of disease after treatment. GSK must continue tracking long-term benefit.FDA
- Cosette lands FDA approval for Evoxac liquid in Sjögren’s diseaseUpdateFDA
ClinicalAstraZeneca's Tezepelumab Posts Positive Phase III CROSSING Results in Eosinophilic Esophagitis · [Articles] Endometrial ablation plus levonorgestrel · Nutritional supplement may help ease 'brain fog' after breast cancer treatment · Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambition …9 ▾▴
Trial starts, early and mid-stage data, and results that did not make the daily.
- AstraZeneca's Tezepelumab Posts Positive Phase III CROSSING Results in Eosinophilic EsophagitisUpdateAstraZeneca China announced positive results from the Phase III CROSSING trial of Taiseido (tezepelumab) in eosinophilic esophagitis. Compared with placebo, patients achieved statistically significant and clinically meaningful histologic remission and symptom improvement at week 24, with efficacy sustained to week 52; at week 52, tezepelumab achieved statistically significant complete endoscopic remission and eliminated endoscopically visible signs of inflammation and fibrosis.
- [Articles] Endometrial ablation plus levonorgestrelUpdateMIRA2, a multicentre, open-label, randomised controlled superiority trial conducted in The Netherlands, showed that endometrial ablation combined with a levonorgestrel-releasing intrauterine system reduced the incidence of hysterectomy in women with heavy menstrual bleeding compared with endometrial ablation alone. The combined treatment appears to be a safe adjunctive strategy that does not increase the risk of complications.
- Nutritional supplement may help ease 'brain fog' after breast cancer treatmentUpdateA small UCLA phase 2 trial found that an oxaloacetate nutritional supplement may improve 'brain fog' after breast cancer treatment. Eighteen women with cognitive impairment following early-stage breast cancer took 500 mg of oxaloacetate twice daily for 8 weeks; 16 completed the trial, with self-rated cognitive scores rising from 29.1 to 55.5, and fatigue and physical functioning also improved. The study had no placebo control, and the team plans a randomized placebo-controlled phase 2 trial.
- Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambitionUpdateA Rapport phase 2 trial in bipolar disorder delivered positive results that won analyst recognition, though it did not meet its original goal. The material provides no specific drug, trial name, sample size, effect size, or safety data, so the magnitude of the results cannot be further assessed.
- STAT+UpdateAt a major European oncology conference, a German biotech presented Phase 1 data for its cell therapy in uveal melanoma: tumors shrank in all 16 patients. Oncologist Sapna Patel noted the target could extend to solid tumors resistant to immunotherapy, such as pancreatic and ovarian cancer.
- Israeli biotech’s inhaled exosome therapy reduces respiratory failure in phase 2 studyUpdate
- casdatifanUpdateAt its R&D day, Arcus Biosciences presented follow-up data on casdatifan, its kidney cancer drug candidate. Analysts believe its efficacy may be superior to Merck's marketed drug Welireg, and the company's shares rose 8% that day.
- Combined estrogen and testosterone therapy increases lumbar spine bone mineral densityUpdate
- Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertaUpdate
Deals and financingMETiS Pharmaceuticals and Eli Lilly Sign LNP Delivery Collaboration Worth Up to About 1.1 Billion Do · Merck KGaA to Acquire Silence Therapeutics for About $1.3 Billion in Cash · Hutchmed Licenses Ex · Alcon to Acquire Neurotech for $550 Million, Gaining Ophthalmic Cell Therapy ENCELTO …7 ▾▴
Licensing, M&A and financing that did not make the daily.
- METiS Pharmaceuticals and Eli Lilly Sign LNP Delivery Collaboration Worth Up to About 1.1 Billion DoUpdateMETiS Pharmaceuticals (Jitai Tech) and Eli Lilly have entered a strategic collaboration on LNP delivery technology. Under the agreement, METiS will receive an upfront payment of over ten million US dollars and is eligible for up to about 1.1 billion US dollars in development, regulatory and commercial milestone payments. METiS will use its AI-driven ionizable lipid discovery and optimization platform AiLNP to develop next-generation LNP delivery technology with improved targeting and biodistribution, while Lilly will provide drug discovery, development and commercialization expertise to support the collaboration.
- Merck KGaA to Acquire Silence Therapeutics for About $1.3 Billion in CashUpdateMerck KGaA has announced a cash acquisition of UK clinical-stage siRNA company Silence Therapeutics for approximately $1.3 billion in equity value, with an enterprise value of $1.1 billion. The company's core asset is a potentially best-in-class siRNA therapy approaching Phase 3 for polycythemia vera. The cash price is $20 per ADS, with each ADS representing three ordinary shares, equivalent to $6.6667 per ordinary share.
- Hutchmed Licenses ExUpdateHutchomed has licensed global development and commercialization rights to HMPL-A830, excluding mainland China, Hong Kong, Macau and Taiwan, to GSK, in a deal totaling $1.295 billion. HMPL-A830 is the third molecule from Hutchmed's in-house ATTC (antibody-targeted conjugate) platform, and its global Phase Ia trial began in September 2026 in both China and the United States.
- Alcon to Acquire Neurotech for $550 Million, Gaining Ophthalmic Cell Therapy ENCELTOUpdateOn October 20, 2026, Alcon announced the acquisition of Neurotech Pharmaceuticals for $550 million, with the core assets being the company's ophthalmic cell therapy platform and ENCELTO, which received FDA approval in March 2025. The deal may also include additional payments tied to commercialization milestones. ENCELTO treats macular telangiectasia type 2 in adults and is the first approved therapy for this indication in the United States.
- Armed CellUpdateFormer Galapagos CEO Paul Stoffels has founded Armed Cell Therapeutics B.V., with Indian drugmaker Mankind Pharma injecting EUR 48 million to become majority shareholder, bringing total funding above EUR 50 million. The company will use the money to revive a preclinical CAR-T pipeline, a year after Galapagos announced its exit from cell therapy and as venture capital interest in cell therapies wanes.
- OpenAI ← Orchestra BioUpdateOpenAI announced the acquisition of drug development platform Orchestra Bio, whose team and technology will be integrated into the Rosalind life sciences system. Orchestra's agents help biopharmaceutical teams track R&D progress and analyze the impact of events such as manufacturing batch failures on clinical trial timelines, then propose responses. The piece notes partnerships with Novo Nordisk and Moderna, and that drug development takes 10 to 15 years on average.
- AntheiaUpdate
OtherCDMO Samsung Bio wins temporary reprieve from strike threat after Seoul court ruling · Compounding Quality Center of Excellence2 ▾▴
Everything else with a concrete event that did not make the daily.
- CDMO Samsung Bio wins temporary reprieve from strike threat after Seoul court rulingUpdateCDMO Samsung Biologues has temporarily defused a strike threat after a Seoul court ruling. The decision is provisional in nature, buying the contract development and manufacturing organization (CDMO) breathing room.
- Compounding Quality Center of ExcellenceUpdateFDA